肝动脉化疗栓塞治疗乙型肝炎相关性肝癌的预后影响因素

银皓; 肖琳; 詹欣宇; 张泽高; 鲁晓擘; 张跃新

doi:10.3969/j.issn.1001-5256.2014.01.011

肝动脉化疗栓塞治疗乙型肝炎相关性肝癌的预后影响因素

DOI: 10.3969/j.issn.1001-5256.2014.01.011

新疆医科大学第一附属医院感染科

基金项目:

新疆医科大学第一附属医院科研奖励基金；新疆维吾尔自治区重点学科(内科学)经费(传染病学学科建设专项基金)(2004-2009)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2624
- HTML全文浏览量: 9
- PDF下载量: 630
- 被引次数: 0
出版历程
- 收稿日期: 2013-02-19
- 出版日期: 2014-01-20

Prognostic factors in patients with hepatitis B- related primary liver cancer treated with transcatheter arterial chemoembolization

Department of Infectious Diseases, The First Affiliated Hospital of Xinjiang Medical University

Research funding:

摘要

摘要:
目的通过分析肝动脉化疗栓塞（TACE）治疗乙型肝炎相关性肝癌的预后影响因素,为临床合理选择适应证及治疗方案提供依据。方法选择自2010年1月到2010年12月在本院行TACE治疗的乙型肝炎相关性肝癌患者140例为研究对象,随访截止日期为2011年12月,观察12个月生存情况。采用Kaplan Meier时序检验及对数秩Log Rank（Mantel-Cox）检验进行单因素及多因素分析,筛选TACE治疗的乙型肝炎相关性肝癌患者的预后影响因素。结果单因素分析结果显示年龄、门静脉转移、腹腔转移、胸腔转移、Child-Pugh分级、胆红素、AST、介入治疗次数、抗病毒治疗对患者预后有影响,TACE联合抗病毒治疗组12个月生存曲线与未抗病毒治疗组有明显差异（P<0.05）。多因素分析结果显示门静脉转移（P=0.004）、腹腔转移（P=0.009）、胆红素水平（P=0.017）、抗病毒治疗（P=0.000）、TACE治疗次数（P=0.000）与TACE治疗的乙型肝炎相关性肝癌患者的预后相关。结论门静脉转移、腹腔转移、胆红素水平可能为影响TACE治疗的乙型肝炎相关性肝癌患者预后的独立危险因素,...
- 肝炎,乙型 /
- 肝肿瘤 /
- 化学栓塞,治疗性 /
- 预后 /
- 因素分析,统计学
Abstract:
Objective To analyze the prognostic factors in patients with hepatitis B- related primary liver cancer treated with transcatheter arterial chemoembolization ( TACE) and to provide a basis for properly selecting indications and treatment regimen in clinical practice. Methods A total of 140 patients with hepatitis B- related primary liver cancer, who underwent TACE in our hospital from January to December 2010, were enrolled in this study. Follow- up was continued until December 2011 to observe the patients' survival within 12 months after treatment. The Kaplan- Meier method and log- rank ( Mantel- Cox) test were used for univariate and multivariate analyses to identify the prognostic factors in patients with hepatitis B- related primary liver cancer treated with TACE. Results The univariate analysis showed that age, portal vein metastasis, peritoneal metastasis, pleural metastasis, Child- Pugh classification, bilirubin, alanine aminotransferase, number of interventional therapies, and antiviral therapy were prognostic factors in patients with hepatitis B- related primary liver cancer treated with TACE. There was significant difference in 12- month survival curve between patients treated with TACE plus antiviral therapy and those who did not receive antiviral therapy ( P < 0. 05) . The multivariate analysis showed that portal vein metastasis ( P = 0. 004) , peritoneal metastasis ( P = 0. 009) , bilirubin level ( P = 0. 017) , antiviral therapy ( P = 0. 000) , and number of TACE therapies ( P = 0. 000) were prognostic factors in patients with hepatitis B- related primary liver cancer treated with TACE. Conclusion Portal vein metastasis, peritoneal metastasis, and bilirubin level may be independent risk factors in patients with hepatitis B- related primary liver cancer treated with TACE, and antiviral therapy and number of interventional therapies may be protective factors for these patients.
- hepatitis B /
- liver neoplasms /
- chemoembolization, therapeutic /
- prognosis /
- factor analysis, statistical

HTML全文

参考文献(14)

[1]SU XQ, YAO DF, XU AB, et al.HCC patients immunity after treatment with Thlidomide combined with transcatheter arterial chemoembolization[J].J Med Res, 2012, 41 (5) :135-137. (in Chinese) 苏小琴, 姚登福, 徐爱兵, 等.肽胺哌啶酮联合TACE治疗原发性肝癌后免疫功能的变化[J].医学研究杂志, 2012, 41 (5) :135-137.

[2]LLOVET JM, REAL MI, MONTAFIA X, et al.Barcelona Liver Cancer Group Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial[J].Lancet, 2002, 359 (9319) :1734-1739.

[3]LO CM, NGAN H, TSO WK, et al.Rnadomized controlled trial of transarterial lipiodol chemoembolization for unreseetable hepatocellular carcinoma[J].Hepatology, 2002, 35 (5) :1164-1171.

[4]LLOVET JM, BRNIX J.Unresectable hepatocellular carcinoma:meta analysis of arterial embolization[J].Radiology, 2004, 230 (1) :300-301.

[5]YANG W, HU NQ, Mo RX.Prognostic factors of TACE primary hepatic carcinoma[J].Chin J Postgradutes Med, 2010, 33 (32) :52-54. (in Chinese) 杨威, 胡虞乾, 莫瑞祥.原发性肝癌肝动脉栓塞化疗术后生存分析[J].中国医师进修杂志, 2010, 33 (32) :52-54.

[6]AHMAD J, RHEE J, CARR BI.The effects of hepatic artery chemotherapy on viral hepatitis in patients with hepatocellular carcinoma[J].Dig Dis Sci, 2005, 50 (2) :331-335.

[7]PENG JW, LIN GN, XIAO JJ, et al.Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapy[J].Asia Pac J Clin Oncol, 2012, 8 (4) :356-361.

[8]JANG JW, CHOI JY, BAE SH.A randomized controlled study of preem-ptive lamivudinein patients receiving transarterial chemo-lipiodolization[J].Hepalology, 2006, 43 (6) :233-240.

[9]KEEFFE EB, DIETERICH DT, HAN SH.A treatment algorithm for the management of chronic hepatitis B virus infection in the United States:an updat[J].Clin Gastruenterol Hepatol, 2006, 4 (8) :936-962.

[10]NAGAMATSU H, ITANO S, NAGAOKA S.Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemothera[J].Am J Gastroenterol, 2004, 99 (12) :2369-2375.

[11]GUO HH, CHAO Y, LI Y, et al.Antiviral treatment influence on life quality of patients with HBV-related primary liver cancer[J].Chin Hepatol, 2012, 17 (2) :83-86. (in Chinese) 郭宏华, 晁阳, 李岩, 等.抗病毒治疗对乙型肝炎相关原发性肝癌患者生活质量及预后的影响[J].肝脏, 2012, 17 (2) :83-86.

[12]WU HY, YOU DH.Lamivudine combined with transcatheter arterial chemoembolization on treatment of advanced hepatocellular carcinoma with cirrhosis[J].Modern J Integr Tradit Chin West Med, 2011, 20 (15) :1833-1834. (in Chinese) 吴杭源, 尤德宏.拉米夫定联合TACE治疗合并肝硬化的中晚期原发性肝癌[J].现代中西医结合杂志, 2011, 20 (15) :1833-1834.

[13]ZHAN GQ, TAN HB, ZHU L, et al.Antiviral effects of transcatheter hepatic arterial chemoembolization on m iddle and advanced stage hepatitis B virus-related liver cancer[J].J Clin Hepatol, 2010, 26 (4) :423-431. (in Chinese) 占国清, 谭华炳, 朱琳, 等.抗病毒对肝动脉化疗栓塞治疗乙型肝炎后中晚期肝癌的作用[J].临床肝胆病杂志, 2010, 26 (4) :423-431.

[14]GUO XP, LIU YW, WAN W, et al.Treatment of liver cirrhosis with postoperative hepatocellular carcinoma with nucleoside analog[J].J Clin Hepatol, 2010, 26 (4) :425-427. (in Chinese) 郭西萍, 刘彦威, 王婉, 等.核苷类抗病毒治疗伴活动性肝硬化肝癌术后的临床观察[J].临床肝胆病杂志, 2010, 26 (4) :425-427.

施引文献

资源附件(0)

访问统计